schliessen

Filtern

 

Bibliotheken

Crosstalk of AP4 and TGFβ receptor signaling in NSCLC

The molecular regulation of growth of non-small cell lung cancer (NSCLC) has not been fully clarified. In NSCLC, we detected significantly higher levels of activating protein-4 (AP4), significantly lower levels of p21, and significantly lower levels of phosphorylated SMAD2 as an indicator of activat... Full description

Journal Title: Tumor Biology 2015, Vol.36(1), pp.447-452
Main Author: Wang, Wei
Other Authors: Wu, Xinyu , Tian, Yu
Format: Electronic Article Electronic Article
Language: English
Subjects:
p21
ID: ISSN: 1010-4283 ; E-ISSN: 1423-0380 ; DOI: 10.1007/s13277-014-2674-6
Link: http://dx.doi.org/10.1007/s13277-014-2674-6
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: springer_jour10.1007/s13277-014-2674-6
title: Crosstalk of AP4 and TGFβ receptor signaling in NSCLC
format: Article
creator:
  • Wang, Wei
  • Wu, Xinyu
  • Tian, Yu
subjects:
  • Activating protein-4
  • Non-small cell lung cancer
  • Transforming growth factor β
  • SMAD2
  • p21
ispartof: Tumor Biology, 2015, Vol.36(1), pp.447-452
description: The molecular regulation of growth of non-small cell lung cancer (NSCLC) has not been fully clarified. In NSCLC, we detected significantly higher levels of activating protein-4 (AP4), significantly lower levels of p21, and significantly lower levels of phosphorylated SMAD2 as an indicator of activated transforming growth factor β (TGFβ) receptor signaling, compared to the adjacent normal lung tissue. Moreover, a strong negative correlation was detected between AP4 and p21 levels. Since p21 is a potent cell-cycle inhibitor, we were thus promoted to examine the relationships among AP4, TGFβ receptor signaling, and cell growth in NSCLC. Using a human NSCLC cell line HepG2 cells, we found that activation of TGFβ receptor signaling increased p21 levels through phosphorylation of SMAD2. Moreover, AP4 inhibited phosphorylation of SMAD2 to contradict the effect of activated TGFβ receptor signaling on cell growth inhibition in NSCLC. Furthermore, binding of TGFβ1 to its receptor also directly increased AP4 transcription, which appeared to negatively control the levels of activated TGFβ receptor signaling. Taken together, our results suggest that AP4 may inhibit the phosphorylation of SMAD2, which is induced by receptor binding with TGFβ1, to abolish the inhibitory effect of activated TGFβ receptor signaling on cell growth in NSCLC. Our study thus highlights AP4 as a novel therapeutic target for NSCLC.
language: eng
source:
identifier: ISSN: 1010-4283 ; E-ISSN: 1423-0380 ; DOI: 10.1007/s13277-014-2674-6
fulltext: no_fulltext
issn:
  • 1423-0380
  • 14230380
  • 1010-4283
  • 10104283
url: Link


@attributes
ID1624649513
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.1007/s13277-014-2674-6
sourceidspringer_jour
recordidTN_springer_jour10.1007/s13277-014-2674-6
sourcesystemOther
pqid1652444992
galeid399902478
display
typearticle
titleCrosstalk of AP4 and TGFβ receptor signaling in NSCLC
creatorWang, Wei ; Wu, Xinyu ; Tian, Yu
ispartofTumor Biology, 2015, Vol.36(1), pp.447-452
identifier
subjectActivating protein-4 ; Non-small cell lung cancer ; Transforming growth factor β ; SMAD2 ; p21
descriptionThe molecular regulation of growth of non-small cell lung cancer (NSCLC) has not been fully clarified. In NSCLC, we detected significantly higher levels of activating protein-4 (AP4), significantly lower levels of p21, and significantly lower levels of phosphorylated SMAD2 as an indicator of activated transforming growth factor β (TGFβ) receptor signaling, compared to the adjacent normal lung tissue. Moreover, a strong negative correlation was detected between AP4 and p21 levels. Since p21 is a potent cell-cycle inhibitor, we were thus promoted to examine the relationships among AP4, TGFβ receptor signaling, and cell growth in NSCLC. Using a human NSCLC cell line HepG2 cells, we found that activation of TGFβ receptor signaling increased p21 levels through phosphorylation of SMAD2. Moreover, AP4 inhibited phosphorylation of SMAD2 to contradict the effect of activated TGFβ receptor signaling on cell growth inhibition in NSCLC. Furthermore, binding of TGFβ1 to its receptor also directly increased AP4 transcription, which appeared to negatively control the levels of activated TGFβ receptor signaling. Taken together, our results suggest that AP4 may inhibit the phosphorylation of SMAD2, which is induced by receptor binding with TGFβ1, to abolish the inhibitory effect of activated TGFβ receptor signaling on cell growth in NSCLC. Our study thus highlights AP4 as a novel therapeutic target for NSCLC.
languageeng
source
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://dx.doi.org/10.1007/s13277-014-2674-6$$EView_full_text_in_Springer_(Subscribers_only)
search
creatorcontrib
0Wang, Wei
1Wu, Xinyu
2Tian, Yu
titleCrosstalk of AP4 and TGFβ receptor signaling in NSCLC
descriptionThe molecular regulation of growth of non-small cell lung cancer (NSCLC) has not been fully clarified. In NSCLC, we detected significantly higher levels of activating protein-4 (AP4), significantly lower levels of p21, and significantly lower levels of phosphorylated SMAD2 as an indicator of activated transforming growth factor β (TGFβ) receptor signaling, compared to the adjacent normal lung tissue. Moreover, a strong negative correlation was detected between AP4 and p21 levels. Since p21 is a potent cell-cycle inhibitor, we were thus promoted to examine the relationships among AP4, TGFβ receptor signaling, and cell growth in NSCLC. Using a human NSCLC cell line HepG2 cells, we found that activation of TGFβ receptor signaling increased p21 levels through phosphorylation of SMAD2. Moreover, AP4 inhibited phosphorylation of SMAD2 to contradict the effect of activated TGFβ receptor signaling on cell growth inhibition in NSCLC. Furthermore, binding of TGFβ1 to its receptor also directly increased AP4 transcription, which appeared to negatively control the levels of activated TGFβ receptor signaling. Taken together, our results suggest that AP4 may inhibit the phosphorylation of SMAD2, which is induced by receptor binding with TGFβ1, to abolish the inhibitory effect of activated TGFβ receptor signaling on cell growth in NSCLC. Our study thus highlights AP4 as a novel therapeutic target for NSCLC.
subject
0Activating protein-4
1Non-small cell lung cancer
2Transforming growth factor β
3SMAD2
4p21
general
010.1007/s13277-014-2674-6
1English
2Springer Science & Business Media B.V.
3SpringerLink
sourceidspringer_jour
recordidspringer_jour10.1007/s13277-014-2674-6
issn
01423-0380
114230380
21010-4283
310104283
rsrctypearticle
creationdate2015
addtitle
0Tumor Biology
1Tumor Markers, Tumor Targeting and Translational Cancer Research
2Tumor Biol.
searchscopespringer_journals_complete
scopespringer_journals_complete
lsr30VSR-Enriched:[pqid, pages, galeid]
sort
titleCrosstalk of AP4 and TGFβ receptor signaling in NSCLC
authorWang, Wei ; Wu, Xinyu ; Tian, Yu
creationdate20150100
facets
frbrgroupid1081745246968425413
frbrtype5
languageeng
creationdate2015
topic
0Activating Protein-4
1Non-Small Cell Lung Cancer
2Transforming Growth Factor Β
3Smad2
4P21
collectionSpringerLink
prefilterarticles
rsrctypearticles
creatorcontrib
0Wang, Wei
1Wu, Xinyu
2Tian, Yu
jtitleTumor Biology
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
aulast
0Wang
1Wu
2Tian
aufirst
0Wei
1Xinyu
2Yu
au
0Wang, Wei
1Wu, Xinyu
2Tian, Yu
atitleCrosstalk of AP4 and TGFβ receptor signaling in NSCLC
jtitleTumor Biology
stitleTumor Biol.
addtitleTumor Markers, Tumor Targeting and Translational Cancer Research
risdate201501
volume36
issue1
spage447
epage452
issn1010-4283
eissn1423-0380
genrearticle
ristypeJOUR
abstractThe molecular regulation of growth of non-small cell lung cancer (NSCLC) has not been fully clarified. In NSCLC, we detected significantly higher levels of activating protein-4 (AP4), significantly lower levels of p21, and significantly lower levels of phosphorylated SMAD2 as an indicator of activated transforming growth factor β (TGFβ) receptor signaling, compared to the adjacent normal lung tissue. Moreover, a strong negative correlation was detected between AP4 and p21 levels. Since p21 is a potent cell-cycle inhibitor, we were thus promoted to examine the relationships among AP4, TGFβ receptor signaling, and cell growth in NSCLC. Using a human NSCLC cell line HepG2 cells, we found that activation of TGFβ receptor signaling increased p21 levels through phosphorylation of SMAD2. Moreover, AP4 inhibited phosphorylation of SMAD2 to contradict the effect of activated TGFβ receptor signaling on cell growth inhibition in NSCLC. Furthermore, binding of TGFβ1 to its receptor also directly increased AP4 transcription, which appeared to negatively control the levels of activated TGFβ receptor signaling. Taken together, our results suggest that AP4 may inhibit the phosphorylation of SMAD2, which is induced by receptor binding with TGFβ1, to abolish the inhibitory effect of activated TGFβ receptor signaling on cell growth in NSCLC. Our study thus highlights AP4 as a novel therapeutic target for NSCLC.
copDordrecht
pubSpringer Netherlands
doi10.1007/s13277-014-2674-6
pages447-452
date2015-01